Project
SAKK 06/19 Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscleinvasive bladder cancer (MIBC).A multicenter, single-arm phase II trial
Ongoing - recruitment active ยท 2022 until 2030
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Status
Ongoing - recruitment active
Start Date
2022
End Date
2030
Financing
SAKK
Study Design
Single Arm Phase 2
Keywords
Urothelkarzinom, muskel-invasiv, BCG, Immuntherapie, neo-adjuvante Chemotherapie
Brief description/objective
Verbesserung der kurativen Therapie des muske-linvasiven Urothelkarzinoms. Durch den Einsatz von BCG lokal in der Blase und perioperativer Immuno-Chemotherapie soll die Ansprechrate verbessert werden